Heterocycle-containing compound, pharmaceutical composition and application
By developing new compounds with high CCR4 antagonism activity, the problem of lack of high-efficiency CCR4 small molecule antagonists in the prior art has been solved, and the potential therapeutic effect on diseases such as atopic dermatitis has been achieved.
CN120192324APending Publication Date: 2025-06-24SHANGHAI PHARMACEUTICALS HOLDING CO LTD
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202411917580.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-24
- Filing Date
- 2024-12-24
- Publication Date
- 2025-06-24
AI Technical Summary
Technical Problem
The prior art has not yet developed a highly active CCR4 small molecule antagonist, which is difficult to effectively treat diseases mediated by CCR4 such as atopic dermatitis.
Method used
A novel compound is provided that has high antagonistic activity against CCR4 by a specific structure such as Formula I, Formula II or Formula III. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of diseases mediated by CCR4.
Benefits of technology
A highly effective antagonism of CCR4 has been achieved, with potential therapeutic effects on atopic dermatitis and other CCR4-related diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses a heterocyclic ring-containing compound, a pharmaceutical composition and application. Specifically, the invention discloses a compound shown as a formula I, a formula II or a formula III or a pharmaceutically acceptable salt thereof. The compound provided by the invention has better inhibitory activity on CCR4, and can be used for treating or preventing diseases mediated by CCR4. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art